EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three divisions: High Intensity Focused Ultrasound (HIFU); Extracorporeal ShockWave Lithotripsy (ESWL); and Distribution. The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
IPO Year: 1997
Exchange: NASDAQ
Website: edap-tms.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2022 | $11.00 | Buy | Jefferies |
| 11/19/2021 | $12.00 → $11.00 | Buy | HC Wainwright & Co. |
Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery LYON, France, November 19, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced a moderated scientific presentation of clinical data comparing Focal One HIFU versus surgery for the treatment of deep infiltrating endometriosis at the 2024 AAGL Global Congress, which took place from November 16-19, 2024, in New Orleans, LA. The presentation was entitled, "Evaluation of rectal endometriosis treatment with high-intensity focused ultrasound versus surgery: a retrospective multicenter study", an
Reported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of EUR 4.5 million (USD 4.9 million), increasing 48.2% over Q3 202334% year-over-year growth in U.S. Focal One HIFU procedures CMS increases Medicare Hospital Outpatient Focal One HIFU procedure payment by 5.4% for 2025Announced AI collaboration with Avenda Health for Focal One Robotic HIFUCompany to host conference call and webcast today, November 7th, at 8:30 a.m. EDT LYON, France, November 7, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the thi
Company to host conference call and webcast on Thursday, November 7th at 8:30am EDT LYON, France, October 24, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2024, before the markets open on Thursday, November 7th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:
LYON, France, October 1, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the Company's proprietary Focal One® robotic high-intensity focused ultrasound (HIFU) technology for the treatment of benign prostatic hyperplasia (BPH). "We've been offering targeted HIFU ablation to prostate cancer patients for more than 15 years," said Harry Toledano, MD, Head of the Urology Department of Martigues Hospital in Martigues, France. "Based on this large experience and the follow-up of hundreds of prostate cancer patients with their functional outcomes, we believ
First Unfold AI®-Assisted Focal One procedures successfully performed at the UCLA School of MedicineFDA-cleared Unfold AI enables urologists to provide tailored, patient-specific Robotic HIFU ablation for prostate cancer patientsEDAP and Avenda Health to present Unfold AI-Assisted Focal One simulated procedures at the 2024 Joint Meeting of the Focal Therapy Society & Society of Urologic Robotic Surgeons in Washington, DC September 19-21, 2024 LYON, France, September 19, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, and Avenda Health ("Avenda"), a leading AI healthcare company, today announ
LYON, France, August 29, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9-11, 2024, in New York City. Date: Tuesday, September 10th Time: 3:00-3:30 PM ET Location: Lotte New York Palace Hotel Webcast: https://journey.ct.events/view/e6563ee2-f715-420c-b29f-ccf7202cc9bd The live and archived webcast of the presentation can be accessed in the Investor
Record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% over Q2 2023Record first half 2024 total worldwide revenue of EUR 30.7 million (USD 33.1 million) increased 5.6% over first half 2023Strong Q2 2024 U.S. Focal One® HIFU procedure growth of +63% year-over-yearCompany to host conference call and webcast today, August 28th, at 8:30 a.m. EDT LYON, France, August 28, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2024. "We continue to see growing demand for our proprietary and leading Focal One robot
Company to host conference call and webcast on Wednesday, August 28th at 8:30am EDT LYON, France, August 7, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2024, before the markets open on Wednesday, August 28th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:Wednesday, A
Semi-Live Focal One Procedure to be Conducted on August 15th at 5:00 pm (KST) LYON, France, August 6, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced that the Company's leading robotic HIFU technology platform, Focal One, will be featured at the 41st World Congress of Endourology and Uro-Technology (WCET 2024) meeting, taking place in Seoul, South Korea, from August 12-16, 2024. "Our leading Focal One platform continues to generate strong interest from the global urology community. EDAP's significant presence at this year's WCET 2024 meeting reflects the increasing trend amongst urologists for utilizing non-invasive HIFU t
Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosisAt three months post procedure, the study's primary endpoint of reduced acute pelvic pain in the HIFU treatment arm compared to the Sham treatment arm was not met Significant improvements were observed across primary and secondary outcome measures (endometriosis and digestive symptoms) across the entire study population at three monthsThe Phase 3 study continues as planned per protocol, with patients from the Sham treatment arm electing HIFU therapy LYON, France, July 19, 2024 - EDAP TMS SA (NASDAQ:
6-K - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
S-8 - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
EFFECT - EDAP TMS SA (0001041934) (Filer)
F-3 - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. "We are pleased to welcome Fran Schulz to our Board of Directors," said Marc Oczachowski, Chairman of the Board of EDAP TMS. "Fran brings a wealth of executive experience in the healthcare industry, and her expertise spans across a broad array of strategic finance and accounting functions. She also possesses an in-depth understanding of U.S. and international regulatory issues, which will further strengthen our Board's leadership as we continue to expand Focal One global
New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology therapeutic applications LYON, France, June 3, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company's European and Middle Eastern commercial leadership. Mr. Desmedt has been appointed Vice President of Sales for Europe, Middle East, Africa, and India (EMEAI), and Mr. Fromm has been appointed General Manager for Switzerland and will
LYON, France, January 2, 2024 - EDAP TMS SA (NASDAQ:EDAP), ("EDAP"), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief Financial Officer of EDAP worldwide, and Francois Dietsch as Global Chief Accounting Officer. Both appointments are effective as of January 1, 2024. "Over the past year, we have continued to align our organization in support of our strategic growth initiatives to build shareholder value by focusing on expanding our operational and commercial presence in the U.S.," said Ryan Rhodes, Chief Executive Officer of EDAP. "Based on Ken's extensive experience in global finance, investor relations and opera
LYON, France, December 6, 2023 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors. Dr. Willsey replaces Dr. Argil Wheelock who has resigned as director of the Company. "I appreciate the opportunity to join the board of EDAP, where the company's Focal One Robotic HIFU platform is changing the treatment paradigm in the management of prostate cancer," said Dr. Lance Willsey. "As a urologist, I have had significant experience in the early evolution of HIFU as a therapeutic modality and have closely followed its clinical development. I have had friend
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value. Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, "I am very pleased to welcome Ken onboard our U.S. subsidiary. Ken is a great addition to Ryan Rh
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:EDAP) with a Buy and maintains $19 price target.
Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosisAt three months post procedure, the study's primary endpoint of reduced acute pelvic pain in the HIFU treatment arm compared to the Sham treatment arm was not metSignificant improvements were observed across primary and secondary outcome measures (endometriosis and digestive symptoms) across the entire study population at three monthsThe Phase 3 study continues as planned per protocol, with patients from the Sham treatment arm electing HIFU therapy
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:EDAP) with a Buy and maintains $19 price target.
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy (RP)Functional evaluation criteria show better results with respect to urinary continence and erectile function in patients receiving HIFU therapy versus patients receiving RPFinal study results were presented during a plenary session of the AUA focused on paradigm-shifting and practice-changing clinical trials in urologyHIFI Study is the largest clinical study ever conducted evaluating treatment outcomes with Focal One robotic HIFU, enrolling a total of 3,328 prospective patients, including 1,9
- SEC Filing
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Edap TMS (NASDAQ:EDAP) with a Buy and raises the price target from $16 to $19.
Edap TMS (NASDAQ:EDAP) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.05) by 200 percent. This is a 7.14 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $21.30 million which beat the analyst consensus estimate of $19.66 million by 8.34 percent. This is a 31.55 percent increase over sales of $16.19 million the same period last year.
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. • REE Automotive (NASDAQ:REE) is estimated to report quarterly loss at $2.38 per share on revenue of $1.35 million. • Precision BioSciences (NASDAQ:DTIL) is projected to report quarterly loss at $2.05 per share on revenue of $12.48 million. • Edap TMS (NASDAQ:EDAP) is expected to report quarterly loss at $0.05 per share on revenue of $19.66 million. • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is expected to report earnings for its fourth quarter. • Cellectar Biosciences (NASDAQ:CLRB) is likely to report earnings for its fourth qua
Reported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of EUR 4.5 million (USD 4.9 million), increasing 48.2% over Q3 202334% year-over-year growth in U.S. Focal One HIFU procedures CMS increases Medicare Hospital Outpatient Focal One HIFU procedure payment by 5.4% for 2025Announced AI collaboration with Avenda Health for Focal One Robotic HIFUCompany to host conference call and webcast today, November 7th, at 8:30 a.m. EDT LYON, France, November 7, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the thi
Company to host conference call and webcast on Thursday, November 7th at 8:30am EDT LYON, France, October 24, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2024, before the markets open on Thursday, November 7th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:
Record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% over Q2 2023Record first half 2024 total worldwide revenue of EUR 30.7 million (USD 33.1 million) increased 5.6% over first half 2023Strong Q2 2024 U.S. Focal One® HIFU procedure growth of +63% year-over-yearCompany to host conference call and webcast today, August 28th, at 8:30 a.m. EDT LYON, France, August 28, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2024. "We continue to see growing demand for our proprietary and leading Focal One robot
Company to host conference call and webcast on Wednesday, August 28th at 8:30am EDT LYON, France, August 7, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2024, before the markets open on Wednesday, August 28th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:Wednesday, A
Strong Q1 2024 U.S. Focal One® HIFU procedure growth of +92% year-over-year Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023Q1 2024 total revenue of EUR 14.9 million ($16.1 million USD) increased 0.8% over Q1 2023Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT LYON, France, May 16, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the first quarter of 2024. "We are off to a strong start in 2024 driven by seven Focal One system placements in the quarter of 2024 and strong year over year procedure growth, reflecting the incre
Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT LYON, France, May 2, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date: Thursday, May 16th
Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022Record full-year 2023 total revenue of EUR 60.4 million ($65.4 million USD) increased 9.6% over full-year 2022Record full-year 2023 HIFU revenue of EUR 20.6 million ($22.3 million USD), an increase of 31.7% over full-year 2022Strong Q4 2023 U.S. Focal One® HIFU procedure growth of +136% year-over-year Company to host conference call and webcast today, March 27th, at 8:30 a.m. EDT LYON, France, March 27, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, re
Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details:
- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year - - Record nine months HIFU revenues reflecting growing demand - - Two additional Focal One systems already placed in the fourth quarter - - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology - - Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT - LYON, France, November 9, 2023 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023. "We continue to see stronger
Company to host conference call and webcast on Thursday, November 9th at 8:30am EDT LYON, France, October 26, 2023 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th, 2023, before the markets open on Thursday, November 9th, 2023. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary. The call will be held at 8:30am EDT on Thursday, November 9th, 2023. Please refer to the information bel
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00
HC Wainwright & Co. reiterated coverage of Edap TMS with a rating of Buy and set a new price target of $11.00 from $12.00 previously
Piper Sandler initiated coverage of Edap TMS with a rating of Overweight and set a new price target of $13.00
HC Wainwright & Co. reiterated coverage of Edap TMS with a rating of Buy and set a new price target of $12.00 from $10.00 previously
Lake Street Capital initiated coverage of Edap Tms with a rating of Buy
B. Riley reiterated coverage of Edap Tms with a rating of Buy and set a new price target of $13.00 from $11.50 previously
HC Wainwright & Co. reiterated coverage of Edap TMS with a rating of Buy and set a new price target of $10 from $6 previously